Tracking new veterinary drug approvals can be frustrating for clinic teams and pet owners alike. Headline announcements often proclaim hundreds of new FDA approvals, yet when practitioners search for novel treatments for canine atopic dermatitis, feline pain, or cardiovascular management, only a small handful of true innovations emerge.

The reason for this disconnect lies in how regulatory databases log actions. A single feed-additive combination for swine or poultry can generate dozens of separate application entries, while generic copies and minor label updates fill out official publishing lists.

To provide clarity, this guide uses data from the FDA Green Book regulatory snapshot to quantify the overall approval landscape for 2025–2026, separates commercial feed additives from companion-animal medicine, and curates the specific new prescription drugs, parasiticides, and formulations that matter for dogs and cats.

The 2025–2026 Approval Landscape: Quantifying the Real Data

Analysis of FDA Center for Veterinary Medicine (CVM) publishing data from 2025 through early 2026 reveals 382 published animal drug application records. However, a detailed breakdown of these records demonstrates why the headline approval count does not reflect 382 brand-new medicines for pets:

[ Total Published Applications: 382 ]
   │
   ├── By Application Type:
   │   ├── NADA (New Animal Drug Applications / Pioneer): 230 (60.2%)
   │   ├── ANADA (Abbreviated New Animal Drug Applications / Generic): 147 (38.5%)
   │   └── CNADA (Conditional Approvals): 5 (1.3%)
   │
   ├── By Regulatory Status:
   │   ├── Approved / Active: 356 (93.2%)
   │   └── Voluntarily Withdrawn: 25 (6.8%)
   │
   └── The Companion-Animal Reality:
       ├── Food-Animal / Medicated Feed Additives: ~75% of entries
       │   (Single sponsor Phibro holds 96 applications for chlortetracycline, etc.)
       └── True Companion-Animal Novel Ingredients / Formulations: < 5%

Key Insights from the Regulatory Data

1. Application Types: Of the 382 published records, 230 represent New Animal Drug Applications (NADA), 147 represent Abbreviated New Animal Drug Applications (ANADA) for bioequivalent generic formulations, and 5 represent Conditional Approvals (CNADA) under expanded access pathways.
2. Sponsor Concentration: The single largest sponsor by record count, Phibro Animal Health, accounts for 96 of the 382 published records (25.1%). These entries consist almost entirely of agricultural medicated feed additives — such as combinations of chlortetracycline, decoquinate, and robenidine for livestock — rather than companion-animal pharmaceuticals.
3. Pioneer vs. Generic: While 60% of entries are listed under NADA, the vast majority are supplemental approvals, manufacturing site updates, or species expansions for long-established compounds. Genuinely new molecular entities (NMEs) for dogs and cats represent less than 5% of total regulatory activity.

Crucial Regulatory Caveat: Publish Date vs. Approval Date

When reviewing FDA Green Book listings, practitioners and researchers must note a key administrative distinction: the Green Book publish_date is not the official FDA approval date.

For example, Numelvi (atinvicitinib) carries an official FDA approval date of February 25, 2026 (NADA 141-596, Freedom of Information Summary), but appeared in monthly Green Book publications under a publish_date of March 9, 2026. The dates cited throughout this article reflect the legal approval dates from FDA Freedom of Information (FOI) summaries and CVM approval notices.

Curated Companion-Animal Spotlight: What Is Truly New

Filtering through agricultural feed additives and routine generic filings leaves a refined list of major companion-animal therapeutic advancements approved or launched in 2025–2026:

1. Numelvi (atinvicitinib tablets) — Next-Generation Canine JAK Inhibitor

• FDA Approval Date: February 25, 2026 (NADA 141-596)
• Target Species: Dogs 6 months of age and older, weighing at least 4.4 lb (2 kg).
• Indication: Control of pruritus (itching) associated with allergic dermatitis.
• Mechanism & Innovation: Atinvicitinib is a highly selective Janus kinase 1 (JAK1) inhibitor developed by Merck Animal Health. By targeted inhibition of JAK1-dependent cytokines (specifically IL-31, IL-2, IL-4, IL-6, and IL-13) while minimizing inhibition of JAK2 (involved in hematopoiesis and erythrocyte production), Numelvi offers rapid itch relief with a refined selectivity profile. It is the only oral JAK inhibitor approved for dogs as young as 6 months — a meaningful age advantage over Zenrelia and Apoquel, which are both labeled for dogs 12 months and older.
• Biochemical Selectivity Profile:
  • JAK1 Inhibition: At least 10-fold selectivity for JAK1 over the other JAK enzymes in vitro, with high potency against IL-31 driven pruritus pathways.
  • JAK2 Sparing: Reduced impact on erythropoietin signaling compared to unselective kinase inhibitors.
  • Dosing Protocol: Once-daily oral administration at or around mealtime.
• Clinical Context: Represents a major competitive addition to the canine dermatology landscape alongside oclacitinib and ilunocitinib. For detailed comparative data, see our in-depth analyses:
  • Numelvi for dogs: JAK inhibitor safety and how it compares
  • Numelvi vs. Apoquel vs. Zenrelia head-to-head comparison

2. Zenrelia (ilunocitinib tablets) — Targeted Dermatology Therapy

• FDA Approval Date: September 19, 2024 (the second oral JAK inhibitor FDA approved for this indication).
• Target Species: Dogs 12 months of age and older.
• Indication: Control of pruritus associated with allergic dermatitis and control of atopic dermatitis.
• Mechanism & Innovation: Developed by Elanco, ilunocitinib is a once-daily oral, non-selective JAK inhibitor engineered for rapid reduction of allergic pruritus and skin lesions without requiring a twice-daily loading phase.
• Clinical Context: Zenrelia established the expanding choice in targeted canine antipruritics. Note the boxed warning and label guidance on vaccination timing; in September 2025 the FDA approved a label update removing earlier "fatal vaccine-induced disease" language after supplemental data showed the relevant hepatitis cases stemmed from natural infection. Explore our full review:
  • Zenrelia for dogs: vaccine timing, boxed warning, and patient selection
  • Zenrelia vs. Apoquel efficacy and safety breakdown

3. Injectable Robenacoxib (ANADA 200-804) — Bioequivalent Post-Operative Analgesia

• FDA Approval Date: March 9, 2026 (ANADA 200-804, Cronus Pharma)
• Target Species: Dogs and Cats (4 months of age and older)
• Indication: The label is species-specific. In dogs, it controls postoperative pain and inflammation associated with soft tissue surgery. In cats, it controls postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy, and castration. Both species are limited to a maximum of 3 days of dosing.
• Mechanism & Innovation: A generic bioequivalent injectable formulation referencing Onsior injection. As a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), robenacoxib provides targeted analgesia while sparing COX-1 mediated gastrointestinal and renal mucosal protection.
• Clinical Protocol: Administered subcutaneously prior to surgery or during anesthesia induction. Provides perioperative pain control with low tissue irritation.
• Clinical Context: Provides hospital teams with a cost-effective, bioequivalent injectable NSAID for surgical protocols. Read our complete analysis:
  • Robenacoxib (Onsior) injection: cat vs dog labels and the 2026 generic

4. BRAVECTO QUANTUM (fluralaner injectable suspension) — Extended Parasiticide Duration

• FDA Approval Date: July 10, 2025 (NADA 141-599, Intervet/Merck Animal Health) — the first FDA-approved product that protects dogs against fleas and ticks for 8 to 12 months from a single injection.
• Target Species: Dogs and puppies 6 months of age and older.
• Indication: Treatment and prevention of flea infestations (Ctenocephalides felis) and treatment and control of tick infestations — black-legged (Ixodes scapularis), American dog (Dermacentor variabilis), and brown dog (Rhipicephalus sanguineus) ticks — for 12 months, and lone star tick (Amblyomma americanum) for 8 months, following a single subcutaneous injection.
• Mechanism & Innovation: Utilizes a sustained-release injectable microparticle formulation of fluralaner (isoxazoline class) to extend systemic ectoparasite protection from 12 weeks (oral chewable) to a full year in a single veterinary visit.
• Clinical Context: Shifts flea and tick compliance from monthly or quarterly owner administration to annual clinic-administered compliance, eliminating compliance lapses in endemic tick regions.

5. Specialized Formulations, Anxiolytics, and Line Extensions

In addition to novel active ingredients, several 2025–2026 approvals focused on critical therapeutic gaps, palatability, and precise dosing:

• Tessie (tasipimidine oral solution): Approved May 6, 2026 (NADA 141-627, Orion Corp.; marketed in the U.S. by Zoetis) as the first FDA-approved therapy for both noise aversion and separation anxiety in dogs. Tasipimidine is a selective alpha-2 adrenoceptor agonist that dampens the heightened fight-or-flight sympathetic activity driving these events; it is dosed by body weight up to three times per 24 hours. Read our Tessie (tasipimidine) deep dive.
• Amodip (amlodipine besylate tablets): Approved April 29, 2026 (NADA 141-613, Ceva) for the control of systemic hypertension in cats — the first FDA-approved feline amlodipine, which improves dosing accuracy and compliance over split human tablets, especially in chronic kidney disease (CKD) patients. See our Amodip (amlodipine) for cats analysis.
• Liavium-CA1 (pregabalin chewable tablets): Conditionally approved in May 2026 (Application 141-606, TriviumVet) for the management of pain and clinical signs associated with Chiari-like malformation and syringomyelia in dogs — a previously unmet neuropathic-pain need that disproportionately affects Cavalier King Charles Spaniels and other small, brachycephalic breeds. See our Liavium-CA1 (pregabalin) deep dive.
• KBroVet (potassium bromide): The first FDA-approved drug for canine idiopathic epilepsy (PRN Pharmacal), which moved from conditional to full approval and formalized quality and consistency standards for a compound long compounded off-label. See our KBroVet (potassium bromide) analysis.
• Credelio Quattro: A multi-parasite combination parasiticide expanding the options owners can get in a single monthly chewable; our Credelio Quattro deep dive covers its four-ingredient coverage and how it compares.

How New Approvals Fit the Regulatory Framework

Understanding how these drugs reach the clinic requires recognizing the pathways established by the FDA Center for Veterinary Medicine:

                          [ FDA CVM Regulatory Pathways ]
                                         │
        ┌────────────────────────────────┼────────────────────────────────┐
        │                                │                                │
  [ NADA Pathway ]              [ ANADA Pathway ]              [ CNADA Pathway ]
  Pioneer / Novel Drug          Generic Bioequivalent          Conditional Access
  Full Safety & Efficacy        Demonstrated Bioequivalence    Unmet Medical Need
  (e.g., Numelvi, Zenrelia)     (e.g., Robenacoxib Injection)  (e.g., Early Oncology)

• Pioneer Approvals (NADA): Require extensive multi-phase clinical field trials establishing target animal safety, clinical efficacy, manufacturing consistency, and environmental impact. For a complete look at the regulatory steps, see how the FDA approves veterinary drugs.
• Generic Bioequivalents (ANADA): Require blood level bioequivalence studies demonstrating identical rate and extent of absorption compared to the pioneer drug. For an evaluation of generic quality standards, see generic animal drugs and ANADA standards.
• Expanded Conditional Approvals (CNADA): Authorized under the FDA's conditional approval pathway (established under minor use/minor species legislation) to allow earlier access for serious or life-threatening conditions where a full effectiveness study is exceptionally difficult — Liavium-CA1 (Chiari-like malformation pain) is a recent example.
• International Regulatory Parallels: Many drugs approved by the US FDA undergo simultaneous or prior evaluation by the European Medicines Agency (EMA). Compare US trends with European approvals in our EMA veterinary medicine approvals analysis.

What Veterinary Teams and Pet Owners Should Watch Next

As 2026 progresses, pipeline developments are expected in several key therapeutic domains:

1. Monoclonal Antibodies for Feline Osteoarthritis and Pain: Building on the clinical adoption of frunevetmab (Solensia) and bedinvetmab (Librela), second-generation target-specific biologics are in development for inflammatory conditions and chronic pruritus.
2. Long-Acting Parasiticide Delivery: Moving beyond oral chewables toward 6-month and 12-month injectable or slow-release transdermal formulations to solve compliance gaps in heartworm and ectoparasite prevention.
3. Targeted Oncology Agents: Expanding conditional approvals (CNADA) for targeted kinase inhibitors and immunotherapies tailored to specific canine mast cell tumors, hemangiosarcoma, transitional cell carcinoma (TCC), and lymphoma sub-types.
4. Feline-Specific Formulations: Increasing emphasis on palatable oral liquids and transdermal gels designed to eliminate the stress of pilling cats with chronic conditions like hyperthyroidism, hypertension, and osteoarthritis.

What to Ask Your Veterinarian

• Is my dog a candidate for newer targeted JAK inhibitors like Numelvi or Zenrelia for chronic allergies?
• How do new extended-duration parasiticides compare to our current monthly preventive protocol?
• Are generic bioequivalent formulations (such as generic robenacoxib injection) available at our clinic to help manage surgical costs?
• What baseline blood work or organ function testing is required before starting a newly approved prescription medication?
• Are there specific vaccination timing guidelines I should follow if my dog is taking a JAK inhibitor?

Frequently Asked Questions

What new dog medications were approved by the FDA in 2026?

The headline companion-animal approval of early 2026 is Numelvi (atinvicitinib), a highly selective oral JAK1 inhibitor approved on February 25, 2026 for control of pruritus associated with allergic dermatitis in dogs as young as 6 months. Bioequivalent generic approvals such as injectable robenacoxib (March 9, 2026) were also logged.

How many new animal drugs are approved each year?

While the FDA Green Book logs between 200 and 400 published application entries annually (382 in 2025–2026), roughly 75% are agricultural medicated feed additives or generic copies. Less than 5% of total entries represent brand-new active ingredients for dogs and cats.

What is the difference between NADA and ANADA approvals?

NADA (New Animal Drug Application) is for pioneer drugs with brand-new active ingredients or novel indications requiring full safety and efficacy trials. ANADA (Abbreviated New Animal Drug Application) is for bioequivalent generic versions of previously approved pioneer drugs.

Why does the Green Book date differ from the FDA approval date?

The Green Book logs monthly administrative publishing dates (publish_date), which occur when monthly tables are updated. The legal approval date is established on the day the FDA CVM signs the Freedom of Information (FOI) Summary.

Is Numelvi the same as Apoquel?

No. While both treat canine allergic itching, Apoquel contains oclacitinib while Numelvi contains atinvicitinib, a novel JAK1 inhibitor developed by Merck Animal Health with a distinct biochemical selectivity profile.

Are generic animal drugs as safe as brand-name pioneer drugs?

Yes. ANADA generic approvals require rigorous bioequivalence testing demonstrating that the generic formulation delivers the exact same active ingredient concentration to the bloodstream at the same rate and extent as the pioneer drug.

Sources

• US Food and Drug Administration, Center for Veterinary Medicine. Freedom of Information Summary: NADA 141-596 (Numelvi / atinvicitinib tablets). Approved February 25, 2026. https://animaldrugsatfda.fda.gov/
• US Food and Drug Administration, Center for Veterinary Medicine. Recent Animal Drug Approvals & Green Book Data Reports (2025–2026). https://www.fda.gov/animal-veterinary/approved-animal-drug-products-green-book
• US Food and Drug Administration, Center for Veterinary Medicine. Freedom of Information Summary: ANADA 200-804 (Robenacoxib Injection). Approved March 9, 2026. https://animaldrugsatfda.fda.gov/
• DailyMed. Prescribing Information: Numelvi (atinvicitinib tablets) for oral use in dogs. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/
• Merck Animal Health. Press Release: FDA Approves Numelvi (atinvicitinib) for Canine Allergic Dermatitis. February 2026. https://www.merck-animal-health.com/
• European Medicines Agency. European Public Assessment Reports (EPAR) for Veterinary Medicines (2025–2026). https://www.ema.europa.eu/en/medicines/field_ema_web_categories%3Aname_field/Veterinary